Status:
UNKNOWN
Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer
Lead Sponsor:
Fudan University
Conditions:
Breast Cancer
Eligibility:
MALE
18-75 years
Brief Summary
Study on the Value of Non-invasive Dual-Pet(18F-FES PET and 68Ga-HER2-Affibody PET) Information in Subtype of Metastatic Breast Cancer
Detailed Description
A Phase II, Single-center STudy on the vAlue of Non-invasive Dual-Pet（18F-FES PET and 68Ga-HER2-Affibody PET）InformatiOn IN Subtype of Metastatic Breast Cancer(MBC)
Eligibility Criteria
Inclusion
- Subjects voluntarily joined the study, signed informed consent, and had good compliance.
- Female patients aged over 18 years (including cutoff value).
- an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Recurrence or metastatic breast cancer confirmed by histopathology, or expect to be feasible metastasis puncture or surgery to confirm histopathological recurrence or metastatic breast cancer.
Exclusion
- Pregnancy or lactation.
- Alcohol allergy is not suitable for FES-PET/ C.
- There are contraindications for patients who are expected to have metastasis puncture or surgery.
- Mental disorders or other conditions affecting patient compliance.
Key Trial Info
Start Date :
December 31 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04758416
Start Date
December 31 2020
End Date
December 31 2022
Last Update
April 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Cancer Center Institutional Review Board
Shanghai, Shanghai Municipality, China